Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108930 | 0.81 | MAOA (0.43) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL7148291 | 0.81 | MAOA (0.47) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL7109799 | 0.81 | MAOA (0.40) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL7103483 | 0.77 | ADRB2 (0.49) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL7107690 | 0.77 | MAOA (0.38) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL7209014 | 0.77 | CLK4 (0.42) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL7109624 | 0.74 | GAA (0.46) | CLK4MAOAADRB2HDAC4KDM1A | |
| SCHEMBL1200615 | 0.73 | SLC18A3 (0.55) | — | |
| SCHEMBL6685962 | 0.72 | CLK4 (0.64) | CLK4ADRB2HDAC4CYP2A6TP53 | |
| SCHEMBL8260386 | 0.71 | GAA (0.40) | TP53ESR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | CLK4 3703/4885MAOA 4332/4885ADRB2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.